Lentiviral vector bioprocess economics for cell and gene therapy commercialization-Reference-Cited by-同舟云学术

Lentiviral vector bioprocess economics for cell and gene therapy commercialization

Published:2021-03 Issue: Volume:167 Page:107868
ISSN:1369-703X
Container-title:Biochemical Engineering Journal
language:en
Short-container-title:Biochemical Engineering Journal

Author:

Comisel Ruxandra-Maria,Kara Bo,Fiesser Frederick H.,Farid Suzanne S.

Funder

Engineering and Physical Sciences Research Council

Publisher

Elsevier BV

Subject

Biomedical Engineering,Environmental Engineering,Bioengineering,Biotechnology

Reference116 articles.

1. Gene therapy clinical trials worldwide to 2017: an update;Ginn;J. Gene Med.,2018

2. Novartis Receives First Ever FDA Approval for a CAR-T Cell Therapy, Kymriah (TM)(CTL019), for Children and Young Adults With B-cell ALL That Is Eefractory or Has Relapsed At Least Twice;NOVARITIS,2020

3. The Market for Chimeric Antigen Receptor T Cell Therapies;Yip,2018

4. Gene therapy’s next installment;Nat. Biotechnol.,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The state of technological advancement to address challenges in the manufacture of rAAV gene therapies;Biotechnology Advances;2024-11

2. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy;Pharmacological Research;2024-10

3. Non‐industrial production of therapeutic lentiviral vectors: How to provide vectors to academic CAR‐T;Biotechnology and Bioengineering;2024-07-04

4. Introducing biosimilar competition for cell and gene therapy products;Journal of Law and the Biosciences;2024-07

5. Augmenting the landscape of chimeric antigen receptor T-cell therapy;Expert Review of Anticancer Therapy;2024-06-26